DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing [Yahoo! Finance]
ImageneBio, Inc. (IMA)
Company Research
Source: Yahoo! Finance
Financing will support the development of novel surfaceome-targeted therapies for hard-to-treat tumors Cologne, Germany, December 11, 2025 – DISCO Pharmaceuticals (“DISCO”) today announced the appointment of seasoned biotech leader Mark Manfredi, Ph.D., as Chief Executive Officer (CEO), as well as the final close of a €36 million seed financing round to advance the company's pipeline of surfaceome-targeted drug candidates. The seed expansion was co-led by Ackermans & van Haaren and NRW.Bank, with participation from existing investors, Sofinnova Partners, AbbVie Ventures, M Ventures, and Panakes Partners. The proceeds will enable DISCO to advance multiple lead antibody-drug conjugate (ADC) candidates in small cell lung cancer (SCLC) and microsatellite-stable colorectal cancer (MSS-CRC) toward IND-enabling studies and expand its pipeline. Dr. Manfredi succeeds the company's founder and founding CEO, Roman Thomas, M.D., who will continue to support the company as a strategic advisor.
Show less
Read more
Impact Snapshot
Event Time:
IMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMA alerts
High impacting ImageneBio, Inc. news events
Weekly update
A roundup of the hottest topics
IMA
News
- ImageneBio (NASDAQ:IMA) is now covered by analysts at Wedbush. They set an "underperform" rating and a $2.00 price target on the stock.MarketBeat
- ImageneBio (NASDAQ:IMA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team [Yahoo! Finance]Yahoo! Finance
- ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management TeamGlobeNewswire
- ImageneBio to Participate in Fourth Quarter 2025 Investor ConferencesGlobeNewswire
IMA
Sec Filings
- 12/22/25 - Form 4
- 12/22/25 - Form 4
- 12/22/25 - Form 4
- IMA's page on the SEC website